NervGen Pharma (NGEN)

• Market cap: $298M
• 1 day: -2.65%
• 5 days: -5.88%
• 1 month: -16.17%
• 3 months: -13%
• 6 months: -38.36%
• Year to date: -38.36%
• 1 year: -38.36%
• 5 years: -38.36%
• 10 years: -38.36%
• Sector: Healthcare
• Industry: Biotechnology

About: NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Employees: 9